FDA Grants Breakthrough Device Designation to AccurKardia's AK+ Guard™ for AI-powered Hyperkalemia Detection

AccurKardia has achieved a significant milestone with the U.S. Food and Drug Administration (FDA) granting Breakthrough Device Designation for its AK+ Guard™ hyperkalemia detection software. This innovative, AI-driven solution leverages Lead I ECG data to assist in identifying moderate to severe episodes of hyperkalemia—a condition characterised by elevated potassium levels in the blood—which can result in sudden cardiac arrest.

The AK+ Guard™ software is compatible with a variety of FDA-cleared consumer and clinical devices, such as smartwatches, that capture Lead I ECG data. This compatibility enables continuous hyperkalemia monitoring outside clinical settings, allowing for earlier interventions, particularly for high-risk groups like those with end-stage renal disease, chronic kidney disease (CKD), and other related conditions.

Recently, AK+ Guard™ was also selected as part of the FDA Total Product Life Cycle Advisory Program (TAP). This programme facilitates earlier and more frequent interactions with the FDA, expediting the regulatory process and improving the overall quality and speed of device evaluations. These developments aim to hasten the commercial availability of the device.

The potential of AK+ Guard™ to transform hyperkalemia monitoring is significant. Hyperkalemia, often asymptomatic, is traditionally diagnosed through blood tests to measure potassium levels. By offering a non-invasive alternative, AK+ Guard™ could extend monitoring capabilities to home settings for at-risk individuals, enhancing care and reducing the burden on healthcare systems.

These achievements mark a crucial step forward for AccurKardia in its mission to enhance patient outcomes and save lives through advanced ECG-based biomarker technology.

The company also recently received FDA Breakthrough Device Designation for its AK-AVS™ software, designed to detect potential cases of aortic valve stenosis (AVS) using existing ECG data within healthcare records. This software aims to prioritise patients requiring further diagnostic testing, underscoring AccurKardia’s commitment to leveraging ECG data to address critical healthcare needs.

Source: https://www.prnewswire.com/news-releases/ventris-medical-receives-510k-clearance-for-innovative-backpack-bone-graft-containment-system-302346449.html